Background: Bipolar disorder (BD) has been associated with temperamental and personality traits, although the relationship is still to be fully elucidated. Several studies investigated the genetic basis of temperament and character, identifying catechol-O-methyltransferase (COMT), brain derived neurotrophic factor (BDNF), and serotonin transporter (5-HTT) gene variants as strong candidates. Methods: In the GECO-BIP study, 125 BD patients and 173 HC were recruited. Subjects underwent to a detailed assessment and the temperament and character inventory 125 items (TCI) was administrated. Three functional genetic variants within key candidate genes (COMT rs4680, BDNF rs6265, and the serotonin-transporter-linked polymorphic region (5-HTTLPR)) were genotyped. Univariate and multivariate analyses were performed. Results: Compared to HC, BD patients showed higher scores in novelty seeking (NS; = 0.001), harm avoidance (HA; p < 0.001), and self transcendence (St; p < 0.001), and lower scores in self directness (p < 0.001) and cooperativeness (p < 0.001) TCI dimensions. Concerning the genetic analyses, COMT rs4680 was associated with NS in the total sample (p = 0.007) and in the male subsample (p = 0.022). When performing the analysis in the HC and BD samples, the association was confirmed only in HC (p = 0.012), and in the HC male subgroup in particular (= 0.004). BDNF rs6265 was associated with St in the BD group (p = 0.017). Conclusion: COMT rs4680 may modulate NS in males in the general population. This effect was not detected in BD patients, probably because BD alters the neurobiological basis of some TCI dimensions. BDNF rs6265 seems to modulate St TCI dimension only in BD patients, possibly modulating the previously reported association between rs6265 and BD treatment response. Further studies are needed to confirm our findings.

1.
Fagiolini A, Forgione R, Maccari M, Cuomo A, Morana B, Dell’Osso MC, Pellegrini F, Rossi A: Prevalence, chronicity, burden and borders of bipolar disorder. J Affect Disord 2013; 148: 161–169.
2.
Laursen TM: Life expectancy among persons with schizophrenia or bipolar affective disorder. Schizophr Res 2011; 131: 101–104.
3.
Dilsaver SC, Chen YW, Swann AC, Shoaib AM, Tsai-Dilsaver Y, Krajewski KJ: Suicidality, panic disorder and psychosis in bipolar depression, depressive-mania and pure-mania. Psychiatry Res 1997; 73: 47–56.
4.
Michalak EE, Yatham LN, Lam RW: Quality of life in bipolar disorder: a review of the literature. Health Qual Life Outcomes 2005; 3: 72.
5.
Oswald P, Souery D, Kasper S, Lecrubier Y, Montgomery S, Wyckaert S, Zohar J, Mendlewicz J: Current issues in bipolar disorder: a critical review. Eur Neuropsychopharmacol 2007; 17: 687–695.
6.
Zaninotto L, Solmi M, Toffanin T, Veronese N, Cloninger CR, Correll CU: A meta-analysis of temperament and character dimensions in patients with mood disorders: Comparison to healthy controls and unaffected siblings. J Affect Disord 2016; 194: 84–97.
7.
Latalova K, Prasko J, Kamaradova D, Sedlackova J, Ociskova M: Comorbidity bipolar disorder and personality disorders. Neuro Endocrinol Lett 2013; 34: 1–8.
8.
Shea MT, Leon AC, Mueller TI, Solomon DA, Warshaw MG, Keller MB: Does major depression result in lasting personality change? Am J Psychiatry 1996; 153: 1404–1410.
9.
Ogle CM, Rubin DC, Siegler IC: Changes in neuroticism following trauma exposure. J Pers 2014; 82: 93–102.
10.
Aldinger F, Schulze TG: Environmental factors, life events, and trauma in the course of bipolar disorder. Psychiatry Clin Neurosci 2017; 71: 6–17.
11.
Barnett JH, Huang J, Perlis RH, Young MM, Rosenbaum JF, Nierenberg AA, Sachs G, Nimgaonkar VL, Miklowitz DJ, Smoller JW: Personality and bipolar disorder: dissecting state and trait associations between mood and personality. Psychol Med 2011; 41: 1593–1604.
12.
Fountoulakis KN, Gonda X, Koufaki I, Hyphantis T, Cloninger CR: The role of temperament in the etiopathogenesis of bipolar spectrum illness. Harv Rev Psychiatry 2016; 24: 36–52.
13.
Cloninger CR, Svrakic DM, Przybeck TR: A psychobiological model of temperament and character. Arch Gen Psychiatry 1993; 50: 975–990.
14.
Akiskal HS: The temperamental borders of affective disorders. Acta Psychiatr Scand Suppl 1994; 379: 32–37.
15.
Di Florio A, Hamshere M, Forty L, Green EK, Grozeva D, Jones I, Caesar S, Fraser C, Gordon-Smith K, Jones L, Craddock N, Smith DJ: Affective temperaments across the bipolar-unipolar spectrum: examination of the TEMPS-A in 927 patients and controls. J Affect Disord 2010; 123: 42–51.
16.
Akiskal HS, Akiskal KK, Lancrenon S, Hantouche E: Validating the soft bipolar spectrum in the French National EPIDEP Study: the prominence of BP-II 1/2. J Affect Disord 2006; 96: 207–213.
17.
Serretti A, Mandelli L, Lorenzi C, Landoni S, Calati R, Insacco C, Cloninger CR: Temperament and character in mood disorders: influence of DRD4, SERTPR, TPH and MAO-A polymorphisms. Neuropsychobiology 2006; 53: 9–16.
18.
Sizoo BB, van der Gaag RJ, van den Brink W: Temperament and character as endophenotype in adults with autism spectrum disorders or attention deficit/hyperactivity disorder. Autism 2015; 19: 400–408.
19.
Saudino KJ: The development of temperament from a behavioral genetics perspective. Adv Child Dev Behav 2009; 37: 201–231.
20.
Kim SJ, Kim YS, Choi NK, Hong HJ, Lee HS, Kim CH: Serotonin transporter gene polymorphism and personality traits in a Korean population. Neuropsychobiology 2005; 51: 243–247.
21.
Service SK, Verweij KJ, Lahti J, Congdon E, Ekelund J, Hintsanen M, Raikkonen K, Lehtimaki T, Kahonen M, Widen E, Taanila A, Veijola J, Heath AC, Madden PA, et al: A genome-wide meta-analysis of association studies of Cloninger’s Temperament Scales. Transl Psychiatry 2012; 2:e116.
22.
Calati R, Signorelli MS, Gressier F, Bianchini O, Porcelli S, Comings DE, De Girolamo G, Aguglia E, MacMurray J, Serretti A: Modulation of a number of genes on personality traits in a sample of healthy subjects. Neurosci Lett 2014; 566: 320–325.
23.
de Moor MH, Costa PT, Terracciano A, Krueger RF, de Geus EJ, Toshiko T, Penninx BW, Esko T, Madden PA, Derringer J, Amin N, Willemsen G, Hottenga JJ, Distel MA, et al: Meta-analysis of genome-wide association studies for personality. Mol Psychiatry 2012; 17: 337–349.
24.
Cloninger CR, Van Eerdewegh P, Goate A, Edenberg HJ, Blangero J, Hesselbrock V, Reich T, Nurnberger J Jr, Schuckit M, Porjesz B, Crowe R, Rice JP, Foroud T, Przybeck TR, et al: Anxiety proneness linked to epistatic loci in genome scan of human personality traits. Am J Med Genet 1998; 81: 313–317.
25.
Ebstein RP: The molecular genetic architecture of human personality: beyond self-report questionnaires. Mol Psychiatry 2006; 11: 427–445.
26.
Balestri M, Calati R, Serretti A, De Ronchi D: Genetic modulation of personality traits: a systematic review of the literature. Int Clin Psychopharmacol 2014; 29: 1–15.
27.
Moore SR, Depue RA: Neurobehavioral foundation of environmental reactivity. Psychol Bull 2016; 142: 107–164.
28.
Calati R, Porcelli S, Giegling I, Hartmann AM, Moller HJ, De Ronchi D, Serretti A, Rujescu D: Catechol-o-methyltransferase gene modulation on suicidal behavior and personality traits: review, meta-analysis and association study. J Psychiatr Res 2011; 45: 309–321.
29.
Giusti L, Provenzi L, Tavian D, Missaglia S, Butti N, Montirosso R: The BDNFval66met polymorphism and individual differences in temperament in 4-month-old infants: a pilot study. Infant behavior and development 2017; 47: 22–26.
30.
Kazantseva A, Gaysina D, Kutlumbetova Y, Kanzafarova R, Malykh S, Lobaskova M, Khusnutdinova E: Brain derived neurotrophic factor gene (BDNF) and personality traits: the modifying effect of season of birth and sex. Prog Neuropsychopharmacol Biol Psychiatry 2015; 56: 58–65.
31.
Benzerouk F, Gierski F, Raucher-Chene D, Ramoz N, Gorwood P, Kaladjian A, Limosin F: Association study between reward dependence and a functional BDNF polymorphism in adult women offspring of alcohol-dependent probands. Psychiatr Genet 2015; 25: 208–211.
32.
Minelli A, Zanardini R, Bonvicini C, Sartori R, Pedrini L, Gennarelli M, Bocchio-Chiavetto L: BDNF serum levels, but not BDNF Val66Met genotype, are correlated with -personality traits in healthy subjects. Eur Arch Psychiatry Clin Neurosci 2011; 261: 323–329.
33.
Gillespie NA, Whitfield JB, Williams B, Heath AC, Martin NG: The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression. Psychol Med 2005; 35: 101–111.
34.
Tuominen L, Salo J, Hirvonen J, Nagren K, Laine P, Melartin T, Isometsa E, Viikari J, Cloninger CR, Raitakari O, Hietala J, Keltikangas-Jarvinen L: Temperament, character and serotonin activity in the human brain: a positron emission tomography study based on a general population cohort. Psychol Med 2013; 43: 881–894.
35.
Spitzer RL, Williams JB, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry 1992; 49: 624–629.
36.
Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L: The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004; 68: 283–297.
37.
Raven J: The Raven’s progressive matrices: change and stability over culture and time. Cogn Psychol 2000; 41: 1–48.
38.
Folstein MF, Robins LN, Helzer JE: The mini-mental state examination. Arch Gen Psychiatry 1983; 40: 812.
39.
Fujioka TA, Chapman LJ: Comparison of the 2-7-8 MMPI profile and the Perceptual Aberration-Magical Ideation Scale in identifying hypothetically psychosis-prone college students. J Consult Clin Psychol 1984; 52: 458–467.
40.
Eckblad M, Chapman LJ: Development and validation of a scale for hypomanic personality. J Abnorm Psychol 1986; 95: 214–222.
41.
Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E: The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. J Autism Dev Disord 2001; 31: 5–17.
42.
Patton JH, Stanford MS, Barratt ES: Factor structure of the Barratt impulsiveness scale. J Clin Psychol 1995; 51: 768–774.
43.
Lipman RS, Covi L, Shapiro AK: The Hopkins Symptom Checklist (HSCL): factors derived from the HSCL-90 (proceedings). Psychopharmacol Bull 1977; 13: 43–45.
44.
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
45.
Bech P, Bolwig TG, Kramp P, Rafaelsen OJ: The Bech-Rafaelsen Mania Scale and the Hamilton Depression Scale. Acta Psychiatr Scand 1979; 59: 420–430.
46.
Wei M, Russell DW, Mallinckrodt B, Vogel DL: The experiences in close relationship scale (ECR)-short form: reliability, validity, and factor structure. J Pers Assess 2007; 88: 187–204.
47.
Kazarian SS, Baker B, Helmes E: The parental bonding instrument: factorial structure. Br J Clin Psychol 1987; 26(pt 3): 231–232.
48.
Paykel ES: Methodological aspects of life events research. J Psychosom Res 1983; 27: 341–352.
49.
Fassone G, Mazzotti E, Trincia V, Pasquini P: Il trauma psicologico infantile in Italia: risultati preliminari su un campione di 273 pazienti psichiatrici afferenti al servizio sanitario nazionale. Riv Psichiatr 2002; 37: 290–296.
50.
Barratt W: The Barratt Simplified Measure of Social Status. 2006. http://wbarratt.indstate.edu/socialclass/Barratt_Simplifed_Measure_of_Social_Status.pdf.
51.
Chisholm D, Knapp MR, Knudsen HC, Amaddeo F, Gaite L, van Wijngaarden B: Client Socio-Demographic and Service Receipt Inventory – European Version: development of an instrument for international research. EPSILON Study 5. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs. Br J Psychiatry Suppl 2000; 39:s28–s33.
52.
Rylander-Rudqvist T, Hakansson N, Tybring G, Wolk A: Quality and quantity of saliva DNA obtained from the self-administrated oragene method – a pilot study on the cohort of Swedish men. Cancer Epidemiol Biomarkers Prev 2006; 15: 1742–1745.
53.
Delvecchio G, Garzitto M, Fagnani C, Fornasari L, Stazi MA, Picardi A, Ciappolino V, Fabbro F, Altamura AC, Brambilla P: Normative data and effects of age and gender on temperament and character dimensions across the lifespan in an Italian population: A cross-sectional validation study. J Affect Disord 2016; 204: 83–91.
54.
Faul F, Erdfelder E, Lang AG, Buchner A: G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175–191.
55.
Cohen J: Statistical Power Analysis for the Bahavioral Sciences. Hillsdale, Taylor & Francis, 1988.
56.
Miettunen J, Lauronen E, Kantojarvi L, Veijola J, Joukamaa M: Inter-correlations between Cloninger’s temperament dimensions – a meta-analysis. Psychiatry Res 2008; 160: 106–114.
57.
Cloninger CR: Feeling Good: The Science of Well-Being. New York, Press OU editor, 2004.
58.
Kyeong S, Kim E, Park HJ, Hwang DU: Functional network organizations of two contrasting temperament groups in dimensions of novelty seeking and harm avoidance. Brain Res 2014; 1575: 33–44.
59.
Clauss JA, Avery SN, Blackford JU: The nature of individual differences in inhibited temperament and risk for psychiatric disease: a review and meta-analysis. Prog Neurobiol 2015; 127–128: 23–45.
60.
Costa VD, Tran VL, Turchi J, Averbeck BB: Dopamine modulates novelty seeking behavior during decision making. Behav Neurosci 2014; 128: 556–566.
61.
Zald DH, Cowan RL, Riccardi P, Baldwin RM, Ansari MS, Li R, Shelby ES, Smith CE, McHugo M, Kessler RM: Midbrain dopamine receptor availability is inversely associated with novelty-seeking traits in humans. J Neurosci 2008; 28: 14372–14378.
62.
Howes OD, McCutcheon R, Owen MJ, Murray RM: The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry 2017; 81: 9–20.
63.
Wingo T, Nesil T, Choi JS, Li MD: Novelty seeking and drug addiction in humans and animals: from behavior to molecules. J Neuroimmune Pharmacol 2016; 11: 456–470.
64.
Grant JE, Leppink EW, Redden SA, Odlaug BL, Chamberlain SR: COMT genotype, gambling activity, and cognition. J Psychiatr Res 2015; 68: 371–376.
65.
Su H, Li Z, Du J, Jiang H, Chen Z, Sun H, Zhao M: Predictors of heroin relapse: personality traits, impulsivity, COMT gene Val158met polymorphism in a 5-year prospective study in Shanghai, China. Am J Med Genet B Neuropsychiatr Genet 2015; 168: 712–719.
66.
Morrow JD, Flagel SB: Neuroscience of resilience and vulnerability for addiction medicine: from genes to behavior. Prog Brain Res 2016; 223: 3–18.
67.
Del Pino-Gutierrez A, Jimenez-Murcia S, Fernandez-Aranda F, Aguera Z, Granero R, Hakansson A, Fagundo AB, Bolao F, Valdeperez A, Mestre-Bach G, Steward T, Penelo E, Moragas L, Aymami N, et al: The -relevance of personality traits in impulsivity-related disorders: From substance use disorders and gambling disorder to bulimia -nervosa. J Behav Addict 2017; 6: 396–405.
68.
Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvadore G: Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 2010; 18: 293–303.
69.
Howes O, McCutcheon R, Stone J: Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol 2015; 29: 97–115.
70.
Suzuki A, Matsumoto Y, Shibuya N, Sadahiro R, Kamata M, Goto K, Otani K: The brain-derived neurotrophic factor Val66Met polymorphism modulates the effects of parental rearing on personality traits in healthy subjects. Genes Brain Behav 2011; 10: 385–391.
71.
Kang JI, Song DH, Namkoong K, Kim SJ: Interaction effects between COMT and BDNF polymorphisms on boredom susceptibility of sensation seeking traits. Psychiatry Res 2010; 178: 132–136.
72.
Turecki G, Ota VK, Belangero SI, Jackowski A, Kaufman J: Early life adversity, genomic plasticity, and psychopathology. Lancet Psychiatry 2014; 1: 461–466.
73.
Rybakowski JK: Response to lithium in bipolar disorder: clinical and genetic findings. ACS Chem Neurosci 2014; 5: 413–421.
74.
Akiskal HS, Mendlowicz MV, Jean-Louis G, Rapaport MH, Kelsoe JR, Gillin JC, Smith TL: TEMPS-A: validation of a short version of a self-rated instrument designed to measure variations in temperament. J Affect Disord 2005; 85: 45–52.
75.
Sullivan PF: Spurious genetic associations. Biol Psychiatry 2007; 61: 1121–1126.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.